FDA approves Lilly's Omvoh for Crohn's disease treatment, expanding its potential market

From Nasdaq MarketSite: 2025-01-15 22:35:50

The FDA has approved Eli Lilly’s Omvoh for treating moderately to severely active Crohn’s disease in adults. Omvoh was previously approved for ulcerative colitis in October 2023. It targets the protein IL-23p19 to reduce inflammation in the gastrointestinal tract, with two-year Phase 3 efficacy data for Crohn’s disease. Lilly has submitted global marketing applications for Omvoh in Crohn’s disease and it is currently approved in 44 countries for UC. Additional regulatory submissions are planned. For more health news, visit rttnews.com.



Read more at Nasdaq MarketSite: FDA Approves Lilly’s Omvoh For Crohn’s Disease Treatment